Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant
- 17 January 2017
- journal article
- research article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 18 (1) , 180-186
Abstract
Tacrolimus (TAC) is highly effective for the prevention of acute organ rejection. However, its clinical use may be challenging due to its large interindividual pharmacokinetic variability, which can be partially explained by genetic variations in TAC-metabolizing enzymes and transporters. The aim of this study was to evaluate the influence of genetic and clinical factors on TAC pharmacokinetic variability in 21 stable pediatric renal transplant patients. This study was nested in a previous Prograf to Advagraf conversion clinical trial. CYP3A5, ABCB1 and two POR genotypes were assessed by real-time PCR. The impact on TAC pharmacokinetics of individual genetic variants on CYP3A5 nonexpressors was evaluated by genetic score. Explicative models for TAC AUC(0-24h), C-max and C-min after Advagraf were developed by linear regression. The built genetic scores explain 13.7 and 26.5% of the total AUC(0-24h) and C-min total variability, respectively. Patients genetic information should be considered to monitorizate and predict TAC exposure.Keywords
This publication has 46 references indexed in Scilit:
- Identification of Factors Affecting Tacrolimus Level and 5‐Year Clinical Outcome in Kidney Transplant PatientsBasic & Clinical Pharmacology & Toxicology, 2012
- Association of MDR1 Gene SNPs and Haplotypes with the Tacrolimus Dose Requirements in Han Chinese Liver Transplant RecipientsPLOS ONE, 2011
- Identification of Cytochrome P450 Oxidoreductase Gene Variants That Are Significantly Associated with the Interindividual Variations in Warfarin Maintenance DoseDrug Metabolism and Disposition, 2011
- Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplantBritish Journal of Clinical Pharmacology, 2009
- Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipientsPharmacogenetics and Genomics, 2006
- Time-Related Clinical Determinants of Long-Term Tacrolimus Pharmacokinetics in Combination Therapy with Mycophenolic Acid and CorticosteroidsClinical Pharmacokinetics, 2004
- TacrolimusDrugs, 2003
- RELATIONSHIP OF FK506 WHOLE BLOOD CONCENTRATIONS AND EFFICACY AND TOXICITY AFTER LIVER AND KIDNEY TRANSPLANTATIONTransplantation, 1996
- AN OPEN-LABEL, CONCENTRATION-RANGING TRIAL OF FK506 IN PRIMARY KIDNEY TRANSPLANTATIONTransplantation, 1996
- Clinical Pharmacokinetics of TacrolimusClinical Pharmacokinetics, 1995